Charleston's Anti-Emetic/Opioid Combo Flops At US FDA Panel Over Postmarketing, Dosage Concerns

 
• By Michael Cipriano

Many of the advisory panel members felt the company's proposed buy-back program could not be feasible in practice.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers